Back to mobile site

Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)

April 8, 2026 6:55 AM EDT Send to a Friend
Guggenheim analyst Seamus Fernandez reiterated a Buy rating and $72.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login